Vaxxinit products

Employs a “multitope” approach to neutralizing the SARS-CoV-2 virus, eliciting a well-balanced B and T-cell response against multiple viral epitopes. Phase 1 and Phase 2 trials of UB-612 have shown UB-612 to be well tolerated, with no significant safety findings to date, and inducing neutralizing titers against Omicron and other variants of concern. UB-612 is now in a Phase 3 heterologous boost trial.